专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1994023725A1 COMPOSITIONS, FOR INHIBITION, CONTROL AND REGRESSION OF ANGIOGENESIS, CONTAINING HYALURONIC ACID AND NSAID 审中-公开
标题翻译：组合物，用于抑制，控制和恢复血液生成，含有羟丙酸和非甾体抗炎药
公开(公告)号：WO1994023725A1
公开(公告)日：1994-10-27
申请号：PCT/CA1994000207
申请日：1994-04-15
申请人： NORPHARMCO INC. , WILLOUGHBY, Derek, A. , ALAM, Chandan , ASCULAI, Samuel, Simon , FALK, Rudolf, Edgar , HARPER, David, William
发明人： NORPHARMCO INC.
IPC分类号： A61K31/725
CPC分类号： A61K31/715 , A61K31/60 , A61K31/54 , A61K31/445 , A61K31/405 , A61K31/40 , A61K31/19
摘要： The use of: (a) a non-steroidal anti-inflammatory agent, and (b) hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid, in the manufacture of a pharmaceutical composition for inhibiting, controlling and/or regressing angiogenesis in a therapy wherein dosage amounts taken from the composition each comprise: (1) a therapeutically effective amount of component (a); and (2) a therapeutically effective amount of the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, the pharmaceutical composition being characterized in that for each dosage amount taken from the pharmaceutical composition, the amount of components (a) and (b) inhibit, control and/or regress angiogenesis.
摘要翻译：使用：（a）非甾体抗炎剂，和（b）透明质酸和/或其盐和/或同系物，类似物，衍生物，复合物，透明质酸的酯，片段和亚单位，在制备用于在治疗中抑制，控制和/或回归血管发生的药物组合物，其中从组合物中取得的剂量各自包括：（1）治疗有效量的组分（a）; 类似物，衍生物，复合物，酯，片段和亚单位的透明质酸的治疗有效量的药物组合物，其特征在于，对于每种剂量取自药物组合物的量，组分（a）和（b）的量抑制，控制和/或退化血管发生。

2. 发明申请

WO1993016732A1 FORMULATIONS CONTAINING HYALURONIC ACID 审中-公开
标题翻译：含有羟丙酸的配方
公开(公告)号：WO1993016732A1
公开(公告)日：1993-09-02
申请号：PCT/CA1993000061
申请日：1993-02-16
申请人： NORPHARMCO INC. , FALK, Rudolf, Edgar , ASCULAI, Samuel, Simon , KLEIN, Ehud, Shmuel , HARPER, David, William , HOCHMAN, David , PURSCHKE, Don
发明人： NORPHARMCO INC.
IPC分类号： A61K47/36
CPC分类号： A61K31/616 , A61K9/0014 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/455 , A61K31/513 , A61K31/5415 , A61K31/70 , A61K31/715 , A61K31/728 , A61K47/36 , A61K2300/00
摘要： Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.
摘要翻译：可以将有效的无毒（对患者）剂量的药物组合物摄取并施用于人的皮肤和/或暴露组织，每种有效剂量包含适于局部施用的药物赋形剂，有效的无毒剂量治疗药物的量和协助解决人的皮肤和/或暴露组织和有效无毒剂量的透明质酸和/或其盐和/或同系物类似物的疾病和/或病症，足以运输（促进或促使药物运输）的透明质酸的衍生物，复合物，酯，片段和/或亚单位，包括皮肤中的部位，包括表皮或暴露的疾病或病症组织，用于经皮运输到皮肤和/或暴露的组织中积累并保持在那里较长的时间段，这是系统的独立作用。

3. 发明申请

WO9530423A3 CANCER TREATMENT AND METASTASIS PREVENTION 审中-公开
标题翻译：癌症治疗和肿瘤预防
公开(公告)号：WO9530423A3
公开(公告)日：1995-12-21
申请号：PCT/CA9500259
申请日：1995-04-28
申请人： NORPHARMCO INC , FALK RUDOLF EDGAR , ASCULAI SAMUEL SIMON
发明人： FALK RUDOLF EDGAR , ASCULAI SAMUEL SIMON
IPC分类号： A61K31/728 , A61K9/00 , A61K31/047 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/375 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/5415 , A61K31/715 , A61K45/06 , A61K47/00 , A61K47/36 , A61P29/00 , A61P35/00 , A61P35/04 , A61K31/725 , A61K31/495 , A61K31/70
CPC分类号： A61K45/06 , A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K31/728 , A61K47/36 , A61K2300/00
摘要： A new method for the treatment of cancer in a human particularly malignant tumors, for example those in a breast or breasts, said method comprising the steps of: (1) directly injecting into the tumour a dosage amount of a pharmaceutical composition comprising an effective amount of an anti-cancer drug and/or drug suitable for use to treat cancer (for example about 1 to about 2 mg Novantrone (Mitoxantrone), other chemotherapeutic agent, NSAIDs) and an effective amount of a form of hyaluronic acid, for example hyaluronic acid and/or pharmaceutically acceptable salts thereof preferably sodium hyaluronate having a molecular weight of less than 750,000 daltons (for example 150,000 - 225,000 daltons) (for example about 10 to about 20 mg sodium hyaluronate) in sterile water; and (2) administering systemically, preferably intravenously, a dosage amount of a pharmaceutical composition comprising: (i) an effective amount of a form of hyaluronic acid (for example hyaluronic acid and/or pharmaceutically acceptable salts thereof, preferably sodium hyaluronate having a molecular weight less than 750,000 daltons (for example 150,000 - 225,000 daltons) for example about 100 - 200 mg or more (because of a lack of toxicity and to reduce the side effects of any medicine (for example NSAID) administered therewith if the amount of the form of hyaluronic acid exceeds about 200 mg/70 kg person); (ii) a drug selected from the group comprising: a) a non-steroidal anti-inflammatory drug (NSAID) for example in an amount of from about 30 mg to about 100 mg (for example 30 to 60 mg of tromethanine salt of ketoralac (sold under the trade mark Toradol) and 50 to 100 mg of diclofenac or diclofenac sodium (for example sold under the trade mark Voltarol), b) an anti-cancer drug, and c) a drug suitable for use to treat cancer and combinations thereof optionally together with (iii) an anti-oxidant for example Vitamin C (in one embodiment 25 gm of Vitamin C).

4. 发明申请

WO1995030423A2 CANCER TREATMENT AND METASTASIS PREVENTION 审中-公开
标题翻译：癌症治疗和肿瘤预防
公开(公告)号：WO1995030423A2
公开(公告)日：1995-11-16
申请号：PCT/CA1995000259
申请日：1995-04-28
申请人： NORPHARMCO INC. , FALK, Rudolf, Edgar , ASCULAI, Samuel, Simon
发明人： NORPHARMCO INC.
IPC分类号： A61K31/725
CPC分类号： A61K45/06 , A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K31/728 , A61K47/36 , A61K2300/00
摘要： A new method for the treatment of cancer in a human particularly malignant tumors, for example those in a breast or breasts, said method comprising the steps of: (1) directly injecting into the tumour a dosage amount of a pharmaceutical composition comprising an effective amount of an anti-cancer drug and/or drug suitable for use to treat cancer (for example about 1 to about 2 mg Novantrone (Mitoxantrone), other chemotherapeutic agent, NSAIDs) and an effective amount of a form of hyaluronic acid, for example hyaluronic acid and/or pharmaceutically acceptable salts thereof preferably sodium hyaluronate having a molecular weight of less than 750,000 daltons (for example 150,000 - 225,000 daltons) (for example about 10 to about 20 mg sodium hyaluronate) in sterile water; and (2) administering systemically, preferably intravenously, a dosage amount of a pharmaceutical composition comprising: (i) an effective amount of a form of hyaluronic acid (for example hyaluronic acid and/or pharmaceutically acceptable salts thereof, preferably sodium hyaluronate having a molecular weight less than 750,000 daltons (for example 150,000 - 225,000 daltons) for example about 100 - 200 mg or more (because of a lack of toxicity and to reduce the side effects of any medicine (for example NSAID) administered therewith if the amount of the form of hyaluronic acid exceeds about 200 mg/70 kg person); (ii) a drug selected from the group comprising: a) a non-steroidal anti-inflammatory drug (NSAID) for example in an amount of from about 30 mg to about 100 mg (for example 30 to 60 mg of tromethanine salt of ketoralac (sold under the trade mark Toradol) and 50 to 100 mg of diclofenac or diclofenac sodium (for example sold under the trade mark Voltarol), b) an anti-cancer drug, and c) a drug suitable for use to treat cancer and combinations thereof optionally together with (iii) an anti-oxidant for example Vitamin C (in one embodiment 25 gm of Vitamin C).
摘要翻译：一种用于治疗人类特别恶性肿瘤（例如乳腺或乳腺中的癌症）的新方法，所述方法包括以下步骤：（1）直接向肿瘤注射剂量的药物组合物，其包含有效量适用于治疗癌症的抗癌药物和/或药物（例如约1至约2mg Novantrone TM（米托蒽醌），其它化学治疗剂，NSAID）和有效量的透明质酸形式，例如透明质酸和/或其药学上可接受的盐，优选在无菌水中分子量小于750,000道尔顿（例如150,000至225,000道尔顿）（例如约10至约20mg透明质酸钠）的透明质酸钠; （2）系统地，优选静脉内施用剂量的药物组合物，其包含：（i）有效量的透明质酸形式（例如透明质酸和/或其药学上可接受的盐，优选透明质酸钠，其具有分子重量小于750000道尔顿（例如150,000至225,000道尔顿），例如约100-200mg或更多（因为缺乏毒性，并减少与其一起施用的任何药物（例如NSAID）的副作用，如果其量透明质酸的形式超过约200mg / 70kg人）;（ii）选自以下的药物：a）非甾体抗炎药（NSAID），例如其量为约30mg至约 100毫克（例如30至60毫克的ketoralac的十五烷醇盐（以商标Toradol出售）和50至100mg的双氯芬酸或双氯芬酸钠（例如以商标Voltarol出售），b）抗癌药，和 c）适合用于治疗癌症的药物及其组合，任选地与（iii）抗氧化剂，例如维生素C（在一个实施方案中为25gm的维生素C）。

5. 发明申请

WO1995026193A1 USE OF HYALURONIC ACID AND FORMS TO PREVENT ARTERIAL RESTENOSIS 审中-公开
标题翻译：使用羟丙酸和抗氧化剂，以防止ARTERIAL RESTENOSIS
公开(公告)号：WO1995026193A1
公开(公告)日：1995-10-05
申请号：PCT/CA1994000188
申请日：1994-03-25
申请人： NORPHARMCO INC. , FALK, Rudolf, Edgar , ASCULAI, Samuel, Simon , TURLEY, Eva, Anne
发明人： NORPHARMCO INC.
IPC分类号： A61K31/73
CPC分类号： A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/455 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/70 , A61K31/715 , A61K31/728 , A61K45/06 , A61K47/10 , A61K47/36 , A61K31/375 , A61K2300/00
摘要： For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid to the animal to prevent narrowing of the tubular walls.
摘要翻译：为了防止管壁创伤后管状壁的变窄，施用治疗有效的无毒量的透明质酸和/或其盐和/或同系物，类似物，衍生物，复合物，透明质酸的酯，片段和亚单位，以防止管壁变窄。

6. 发明申请

WO1997040841A1 USE OF FORMES F HYALURONIC ACID (HA) FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：用于治疗癌症的肝素（HA）的使用
公开(公告)号：WO1997040841A1
公开(公告)日：1997-11-06
申请号：PCT/CA1997000283
申请日：1997-04-28
申请人： HYAL PHARMACEUTICAL CORPORATION , FALK, Rudolf, Edgar
发明人： HYAL PHARMACEUTICAL CORPORATION
IPC分类号： A61K31/715
CPC分类号： A61K31/728
摘要： A method is provided for the treatment of cancer comprising administering orally or systemically (intravenously preferably) of an effective dosage amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof as the only therapeutic agent, in a diluent, in such amounts and over such period of time to permit the successful treatment of cancer.
摘要翻译：提供了一种治疗癌症的方法，其包括以有效剂量的量选自透明质酸和其药学上可接受的盐作为唯一治疗剂的透明质酸形式的口服或全身（静脉内优选），在稀释剂，以这样的量和这样的时间段允许成功治疗癌症。

7. 发明申请

WO1995029683A1 PHARMACEUTICAL COMPOSITION COMPRISING HYALURONIC ACID FOR THE CLEARING OF ARTERIOSCLEROSIS 审中-公开
标题翻译：含有羟丙酸的药物组合物用于清除神经节细胞
公开(公告)号：WO1995029683A1
公开(公告)日：1995-11-09
申请号：PCT/CA1995000243
申请日：1995-04-27
申请人： NORPHARMCO INC. , FALK, Rudolf, Edgar , ASCULAI, Samuel, Simon
发明人： NORPHARMCO INC.
IPC分类号： A61K31/725
CPC分类号： A61K31/728 , A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K45/06 , A61K47/36 , A61K2300/00 , A61K31/375 , A61K31/198
摘要： A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof, homologues, analogues, derivatives, esters, complexes, fragments and subunits.
摘要翻译：一种清除动脉粥样硬化的方法，包括向患者施用至少一个剂量的药物组合物的步骤，所述药物组合物包含有效无毒量的螯合剂，非甾体抗炎药（NSAID），非甾体抗炎药抗氧化剂和透明质酸形式，其选自透明质酸，其盐，同系物，类似物，衍生物，酯，复合物，片段和亚单位。

8. 发明申请

WO1991004058A2 TREATMENT OF CONDITIONS AND DISEASE 审中-公开
标题翻译：治疗病情和疾病
公开(公告)号：WO1991004058A2
公开(公告)日：1991-04-04
申请号：PCT/CA1990000306
申请日：1990-09-18
申请人： NORPHARMCO INC. , FALK, Rudolf, Edgar , ASCULAI, Samuel, S.
发明人： NORPHARMCO INC.
IPC分类号： A61K47/36
CPC分类号： A61K9/0019 , A61K9/0014 , A61K31/10 , A61K31/13 , A61K31/19 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/375 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/54 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K31/728 , A61K45/06 , A61K47/36 , A61K47/61 , Y10S514/886 , Y10S514/887 , A61K2300/00
摘要： A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
摘要翻译：用于给予哺乳动物的组合，其组合使用治疗有效量的药物和/或治疗剂来治疗疾病或病症以及一定量的透明质酸和/或其盐和/或同系物，类似物，衍生物，复合物，透明质酸的酯，片段和亚单元，其足以促进试剂穿过待处理部位的组织（包括瘢痕组织）穿过细胞膜渗透到待治疗的个体细胞中。

9. 发明申请

WO1997003699A1 USE OF HYALURONIC ACID AND A NSAID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MUCOSAL DISEASES 审中-公开
标题翻译：用于治疗粘膜疾病的药物的制备使用羟丙酸和非甾体抗炎药
公开(公告)号：WO1997003699A1
公开(公告)日：1997-02-06
申请号：PCT/CA1996000488
申请日：1996-07-18
申请人： HYAL PHARMACEUTICAL CORPORATION , ASCULAI, Samuel, Simon , FALK, Rudolf, Edgar , RUSSELL, Alan, L.
发明人： HYAL PHARMACEUTICAL CORPORATION
IPC分类号： A61K47/36
CPC分类号： A61K9/006 , A61K47/36
摘要： The use of an effective amount of a composition comprising an N.S.A.I.D. and a form of hyaluronic acid selected from hyaluronic acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof for mucous membrane trauma, disease, and/or pain relief.
摘要翻译：使用有效量的组合物，其包含N.S.A.I.D. 以及选自透明质酸，其药学上可接受的盐，其片段和/或其亚基的透明质酸形式用于粘膜创伤，疾病和/或疼痛缓解。

10. 发明申请

WO1994007505A1 USE OF HYALURONIC ACID AND FORMS TO PREVENT ARTERIAL RESTENOSIS 审中-公开
标题翻译：使用羟丙酸和抗氧化剂，以防止ARTERIAL RESTENOSIS
公开(公告)号：WO1994007505A1
公开(公告)日：1994-04-14
申请号：PCT/CA1993000388
申请日：1993-09-22
申请人： NORPHARMCO INC. , FALK, Rudolf, Edgar , ASCULAI, Samuel, Simon , TURLEY, Eva, Anne
发明人： NORPHARMCO INC.
IPC分类号： A61K31/725
CPC分类号： A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/455 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/70 , A61K31/715 , A61K31/728 , A61K45/06 , A61K47/10 , A61K47/36 , A61K2300/00
摘要： For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid to the animal to prevent narrowing of the tubular walls.
摘要翻译：为了防止在管状壁被创伤后动物的管状壁变窄，施用治疗有效的无毒量的透明质酸和/或其盐和/或同系物，类似物，衍生物，复合物，透明质酸的酯，片段和亚单位，以防止管壁变窄。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式